References
- Frølich A, McNair P, Transbøl I. Awareness of hypercalcaemia in a hospital population?. Scand J Clin Lab Invest 1991; 51: 37–41
- Link K, Centor R, Buchsbaum D, Winterspoon J. Why physicians don't pursue abnormal laboratory tests: An investigation of hypercalcemia and the follow‐up of abnormal test results. Human Pathol 1984; 15: 75–8
- Rajathurai A, Cove‐Smith R. Hypercalcaemia in Cleveland: a hospital‐based survey. J Roy Soc Med 1984; 77: 742–6
- Dent D M, Miller J L, Klaff L, Barron J. The incidence and causes of hypercalcaemia. Postgrad Med J 1987; 63: 745–50
- Diamond T H, Botha J R, Vermaak W JH, Kalk W J. Hypercalcaemia in the Johannesburg Hospital. Differential diagnosis and physician awareness of primarv hyperparathyroidism. S Afr Med J 1987; 72: 113–5
- McDonald C J, Hui S L, Smith D M, Tierney W M, Cohen S J, Weinberger M, McCabe G P. Reminders to physicians from an introspective computer medical record. Ann Intern Med 1984; 100: 130–8
- Frølich A, Nielsen B F, Conradsen K, McNair P. Filtering clinically significant hypercalcemia from non‐significant hypercalcemia at the laboratory level. Scand J Clin Lab Invest 1993; 53: 215–23
- Hedbäck G, Oden A. Clinical evaluation of total serum calcium in primary hyperparathyroidism and the risk of death after surgery. Eur J Clin Invest 1995; 25: 48–52
- Bajorunas D R. Disorders of endocrine function in the critically ill cancer patient. Critical care of the cancer patient, W S Howland, G C Carlon. Year Book Medical, Chicago 1985; 143–72
- Myers W PL. Hypercalcemia associated with malignant diseases. Endocrine and nonendo‐crine hormone‐producing tumors. Year Book Medical, Chicago 1973; 147–71
- Berenson J R, Lichtenstein A, Porter L, Dimo‐poulos M A, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–93
- Ralston S H, Gallacher S J, Patel U, Campbell J, Boyle I T. Cancer‐associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112: 499–504
- Biermann W A, Cantor R I, Fellin F M, Jakobowski J, Hopkins L, Newbold R C. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12(Suppl 1)S37–S42
- Frølich A, Nielsen B F, Conradsen K, McNair P, Transbøl I. Within‐centre evaluation of hypercalcemia discriminant functions five years after their development. Int J Biomed Comput 1996; 40: 235–40
- Frølich A, Nielsen B F, Nielsen J, Conradsen K, McNair P. Do local hospitals meet the analytical goals for the use of common reference intervals?. Scand J Clin Lab Invest 1994; 54: 169–76